Lycorine Attenuates Autophagy in Osteoclasts via an Axis of mROSTRPML1TFEB to Reduce LPS-Induced Bone Loss

Abstract EN

Lycorine, a plant alkaloid, exhibits anti-inflammatory activity by acting in macrophages that share precursor cells with osteoclasts (OCs).

We hypothesized that lycorine might decrease bone loss by acting in OCs after lipopolysaccharide (LPS) stimulation, since OCs play a main role in LPS-induced bone loss.

Microcomputerized tomography (μCT) analysis revealed that lycorine attenuated LPS-induced bone loss in mice.

In vivo tartrate-resistant acid phosphatase (TRAP) staining showed that increased surface area and number of OCs in LPS-treated mice were also decreased by lycorine treatment, suggesting that OCs are responsible for the bone-sparing effect of lycorine.

In vitro, the increased number and activity of OCs induced by LPS were reduced by lycorine.

Lycorine also decreased LPS-induced autophagy in OCs by evaluation of decreased lipidated form of microtubule-associated proteins 1A/1B light chain 3B (LC3) (LC3II) and increased sequestosome 1 (p62).

Lycorine attenuated oxidized transient receptor potential cation channel, mucolipin subfamily (TRPML1) by reducing mitochondrial reactive oxygen species (mROS) and decreased transcription factor EB (TFEB) nuclear translocation.

Lycorine reduced the number and activity of OCs by decreasing autophagy in OCs via an axis of mROS/TRPML1/TFEB.

Collectively, lycorine protected against LPS-induced bone loss by acting in OCs.

Our data highlight the therapeutic potential of lycorine for protection against inflammatory bone loss.